Search
Mivacurium
go.drugbank.com/drugs/DB01226ApprovedWithdrawnIt binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalIt is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. … By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the
Ibrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235384] Ibrexafungerp is orally bioavailable compared to the echinocandins [caspofungin], [micafungin], and [anidulafungin]; which can only be administered parenterally.
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[L16028] Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure … [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal
Ximelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnwhere the drug had been approved. … Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils. … [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigationalCemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. … By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
Categories: Programmed Death Receptor-1 Blocking AntibodyAtorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigationalBy inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. … More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid.
Mixtures: EZETIMIBE E ATORVASTATINA DOC, EZETIMIBE E ATORVASTATINA DOCCerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnOn August 8, 2001 the U.S. … It has also been withdrawn from the Canadian market.[A669,L43942]
Fluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigational[A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body. … Fluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging.